Stratum Nutrition (St. Louis, MO) has announced that the company, in collaboration with its European partner KitoZyme (Herstal, Belgium), will soon begin a six-week human clinical study on Artinia, a chitin-glucan fiber marketed for heart health.
Stratum Nutrition (St. Louis, MO) has announced that the company, in collaboration with its European partner KitoZyme (Herstal, Belgium), will soon begin a six-week human clinical study on Artinia, a chitin-glucan fiber marketed for heart health.
Thus far, a 12-week animal and 30-day human pilot study have been performed on the ingredient. The upcoming study, which has received approval frmo an Institutional Review Board, will be randomized, double-blind, and placebo-controlled at three clinical sites. Biomarkers to be measured will include the oxidation of low-density lipoprotein (LDL or 'bad'ÃÂ cholesterol), lipids, insulin, and other markers related to inflammation and human safety.
The study is expected to be completed by the end of this year. For more information on the ingredient, visit Stratum Nutrition here.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.